The changing treatment landscape of EGFR-mutant non-small-cell lung cancer

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Epidermal Growth Factor Receptor (EGFR) mutations are key drivers in non-small-cell lung cancer (NSCLC).
• EGFR tyrosine-kinase inhibitors (TKIs) have transformed NSCLC treatment, with third-generation TKIs as current first-line standard for advanced EGFR-mutant NSCLC.
• Central nervous system (CNS) penetrance is a notable characteristic of third-generation EGFR TKIs.

Purpose of the Study:

• To review current first-line treatment strategies for EGFR-mutant NSCLC.
• To elucidate mechanisms of acquired resistance to third-generation EGFR TKIs.
• To explore novel and promising therapeutic approaches for managing EGFR-mutant NSCLC, including resistance settings.

Main Methods:

• Comprehensive literature review of current and emerging treatments for EGFR-mutant NSCLC.
• Analysis of resistance mechanisms to third-generation EGFR TKIs.
• Exploration of rational drug combinations and novel therapeutic modalities.

Main Results:

• Third-generation EGFR TKIs are the standard first-line therapy for advanced EGFR-mutant NSCLC.
• Combinatorial strategies (e.g., with anti-angiogenic drugs, chemotherapy, amivantamab) and early-stage TKI use are under investigation.
• Emerging treatments like new TKIs, antibody-drug conjugates, immunotherapies, and targeted protein degraders show promise against acquired resistance.

Conclusions:

• Optimizing first-line therapy and developing strategies to overcome acquired resistance are critical for improving outcomes in EGFR-mutant NSCLC.
• Investigating novel combinations and therapeutic agents is essential to address treatment challenges and enhance patient survival.
• Future research should focus on innovative approaches to achieve long-term disease control and potential cures for NSCLC patients with EGFR mutations.